Acuitas: noun, insight, perception, sharpness.

Thomas Redelmeier Ph.D., Chief Scientific Officer

Thomas RedelmeierPrior to joining Acuitas, Dr. Redelmeier was the President & CEO of Transferra Nanosciences (formerly known as Northern Lipids). He led the company for 20 years, transforming it into a recognized leader in the provision of Contract Research/Manufacturing services specifically related to lipid nanoparticle formulations of active pharmaceutical ingredients. The company was sold to EVONIK in 2016, where it continues to be active in this area.

Dr. Redelmeier has more than 30 years of experience studying lipid nanoparticle (LNP) systems including 20 years at Transferra where he was involved with more than 25 programs that were undergoing preclinical and clinical development. His extensive experience covers LNP formulations of small molecules and nucleic acids and includes the chemistry, manufacturing and control (CMC) of these complex delivery systems.

Our History

Acuitas Therapeutics is a private company incorporated in British Columbia, Canada. We were founded in February 2009 (initially as AlCana Technologies) and have partnered with Alnylam Pharmaceuticals, the University of British Columbia, IRAP and others on several research and development programs relating to systemic delivery of nucleic acid therapeutics.
Contact Information

Twitter Feed

Find out what's happening, right now, with Acuitas Therapeutics.


Copyright 2018 Acuitas Therapeutics. Web Design by Tommy Le Inc.